Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Annexuzlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Annexuzlimab is under development for the treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and solid tumors including triple-negative breast cancer, bile duct cancer (cholangiocarcinoma), bladder cancer, colorectal cancer, ovarian cancer, kidney cancer (renal cell cancer), liver cancer, metastatic pancreatic cancer, gastric cancer, prostate cancer, lung cancer. It is a humanized monoclonal antibody targeting annexin-1. It is administered by intravenous route.
MedAnnex is a biotechnology company that provides monoclonal antibodies. The company provides development of new treatments for autoimmune diseases. It provides annexuzlimab, a specific monoclonal antibody used to treat complex autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus among others. Annexuzlimab targets annexin-1, which is over-expressed in patients suffering from autoimmune diseases. The company provides obstructing annexin-1 with annexuzlimab, in experimental models, led to the reversal of progression of many autoimmune diseases. It also provides non-clinical testing programs. MedAnnex is headquartered in Edinburgh, Scotland, the UK.
For a complete picture of Annexuzlimab’s drug-specific PTSR and LoA scores, buy the report here.